TRX1 is directed at the CD4 antigen
on T cells and has been designed and genetically modified to generate tolerogenic immune responses.
298280B1 relates specifically to engineered red blood cells and liposomes, which have incorporated the human CD4 antigen
into their plasma or lipid membranes, and which may contain one or more cytotoxic agents capable of destroying any cells which fuse with the engineered liposomes.
FIRST PRODUCT APPLICATION OF PRIMATIZED ANTIBODY TECHNOLOGY As a practical first step, IDEC Pharmaceuticals' scientists immunized macaque monkeys with the human CD4 antigen
and harvested the resulting antibody-producing immune cells, without harm to the animal.
As a practical first step," Newman said, "we immunized macaques with the human CD4 antigen
and harvested the resulting antibody- producing immune cells.